Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have experience developing new and innovative bio-assays for different target classes using technologies to deliver client projects in a timely, efficient and cost-effective manner.
Using Promega’s NanoBRET technology, Aurelia Bioscience has implemented intracellular kinase assays designed to study the interaction of compounds on kinase and HDAC targets in intact living cells. NanoBRET Target Engagement Assay measures compound binding at specific target kinases and HDACs. This quantitative analysis can be performed in cultured cells via energy transfer between a 19-kDa luciferase (NanoLuc, Nluc)-tagged target protein and a cell-permeable fluorescent energy transfer probe (tracer) introduced to the assay medium.
Addition of competing compounds results in a dose- and time-dependent decrease in NanoBRET signal, which allows quantification of the intracellular affinity and kinetics of the target kinase or HDAC for the test compound.
This technique is compatible with analysis under equilibrium conditions, suitable for a range of throughput requirements and a good predictor of cellular potency.
Watch the video to learn more about this technology, how it works and some of its key advantages.
